XLONANP
Market cap83mUSD
Jan 02, Last price
392.00GBP
1D
1.29%
1Q
18.94%
Jan 2017
36.05%
IPO
55.14%
Name
Anpario PLC
Chart & Performance
Profile
Anpario plc, together with its subsidiaries, produces and distributes natural feed additives for animal health, hygiene, and nutrition. Its health and performance category offers various products that support and maintain animal gut health, such as phytogenic and acid based eubiotics, and omega fatty acids under the Orego-Stim, Optomega, pHorce, Salgard, Salkil, Genex, and Optimax brands; feed quality category provides products, such as enzymes, antioxidants, pellet binders, mould inhibitors, and acid based eubiotics under the pHorce, Salkil, Salgard, Oxigard, Moldgard, and Mastercube brands. The company's hygiene and insect control category contain products, such as water sanitation tablets, 100% natural insect control powders, and natural drying agents that minimizes the environmental microbial burden, supports the gut health, and animal performance under the Credence, Mitex, Red Lite, and Clean & Dry brands; and toxin management category products, such as mycotoxin binders under the Anpro, Ultrabond, and Neutox brands. It has operations in the Americas, Asia, Europe, the Middle East, and Africa. The company was formerly known as Kiotech International plc and changed its name to Anpario plc in November 2011. Anpario plc was founded in 1996 and is headquartered in Worksop, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 30,998 -6.36% | 33,103 -0.79% | |||||||
Cost of revenue | 28,475 | 29,497 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 2,523 | 3,606 | |||||||
NOPBT Margin | 8.14% | 10.89% | |||||||
Operating Taxes | 225 | 378 | |||||||
Tax Rate | 8.92% | 10.48% | |||||||
NOPAT | 2,298 | 3,228 | |||||||
Net income | 2,528 -23.46% | 3,303 -29.47% | |||||||
Dividends | (1,762) | (2,186) | |||||||
Dividend yield | 3.64% | 2.00% | |||||||
Proceeds from repurchase of equity | (9,123) | 295 | |||||||
BB yield | 18.86% | -0.27% | |||||||
Debt | |||||||||
Debt current | 33 | 35 | |||||||
Long-term debt | 125 | 34 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 46 | 825 | |||||||
Net debt | (10,744) | (13,651) | |||||||
Cash flow | |||||||||
Cash from operating activities | 8,695 | 1,211 | |||||||
CAPEX | (277) | (1,540) | |||||||
Cash from investing activities | 1,211 | (1,565) | |||||||
Cash from financing activities | (10,960) | (1,964) | |||||||
FCF | 6,561 | (222) | |||||||
Balance | |||||||||
Cash | 10,649 | 13,567 | |||||||
Long term investments | 253 | 153 | |||||||
Excess cash | 9,352 | 12,065 | |||||||
Stockholders' equity | 29,484 | 38,676 | |||||||
Invested Capital | 24,422 | 29,954 | |||||||
ROIC | 8.45% | 11.45% | |||||||
ROCE | 7.10% | 8.24% | |||||||
EV | |||||||||
Common stock shares outstanding | 18,789 | 21,874 | |||||||
Price | 2.58 -48.50% | 5.00 -18.83% | |||||||
Market cap | 48,382 -55.76% | 109,370 -19.76% | |||||||
EV | 37,638 | 95,719 | |||||||
EBITDA | 3,760 | 4,831 | |||||||
EV/EBITDA | 10.01 | 19.81 | |||||||
Interest | 6 | 3 | |||||||
Interest/NOPBT | 0.24% | 0.08% |